Clinical Research Directory
Browse clinical research sites, groups, and studies.
Carbon Ion Re-Radiotherapy in Patients With Recurrent or Progressive Locally Advanced Head-and-Neck Cancer
Sponsor: University Hospital Heidelberg
Summary
After multimodal therapy of head-and-neck tumors, patients often develop local recurrence, locally progressive disease or second primary tumors. In this highly pre-treated patient cohort, therapeutic options are limited. Patients that are not candidates for salvage surgery may benefit from re-irradiation. Despite recent technical advances, re-irradiation is associated with severe side effects. Carbon ion Re-Radiotherapy (reCIRT) has shown encouraging results in retrospective analyses with moderate toxicity. In the current Phase-II CARE-trial, reCIRT and conventional photon re-irradiation in patients with recurrent or progressive locally advanced head-and-neck cancer will be assessed regarding toxicity/ safety, local progression-free survival, overall survival and quality-of-life.
Official title: Carbon Ion Re-Radiotherapy in Patients With Recurrent or Progressive Locally Advanced Head-and-Neck Cancer: A Phase-II Study to Evaluate Toxicity and Efficacy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
72
Start Date
2020-08-25
Completion Date
2031-01-30
Last Updated
2026-03-25
Healthy Volunteers
No
Conditions
Interventions
C12 re-irradiation
51 Gy(RBE) or 54 Gy
Photon re-irradiation
54 Gy(RBE) or 60 Gy
Locations (2)
University Hospital of Heidelberg, Radiation Oncology
Heidelberg, Germany
Philips University Marburg
Marburg, Germany